Baudax Bio Inc. [NASDAQ: BXRX] loss -6.60% or -0.01 points to close at $0.20 with a heavy trading volume of 2332395 shares. The company report on January 4, 2022 that Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference.
Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10 – 13, 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The presentation will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.
It opened the trading session at $0.2165, the shares rose to $0.2165 and dropped to $0.196, the range by which the price of stock traded the whole day. The daily chart for BXRX points out that the company has recorded -67.69% loss over the past six months. However, it is still -5.26% lower than its most recent low trading price.
If we look at the average trading volume of 2.40M shares, BXRX reached to a volume of 2332395 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Baudax Bio Inc. [BXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BXRX shares is $1.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BXRX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Baudax Bio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 15, 2020.
The Average True Range (ATR) for Baudax Bio Inc. is set at 0.03, with the Price to Sales ratio for BXRX stock in the period of the last 12 months amounting to 20.96.
Trading performance analysis for BXRX stock
Baudax Bio Inc. [BXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.76. With this latest performance, BXRX shares dropped by -40.54% in over the last four-week period, additionally sinking by -67.69% over the last 6 months – not to mention a drop of -85.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BXRX stock in for the last two-week period is set at 27.07, with the RSI for the last a single of trading hit 25.79, and the three-weeks RSI is set at 28.53 for Baudax Bio Inc. [BXRX]. The present Moving Average for the last 50 days of trading for this stock 0.3597, while it was recorded at 0.2086 for the last single week of trading, and 0.6469 for the last 200 days.
Baudax Bio Inc. [BXRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Baudax Bio Inc. [BXRX] shares currently have an operating margin of -11319.88 and a Gross Margin at -769.37. Baudax Bio Inc.’s Net Margin is presently recorded at -15436.11.
Reflecting on the efficiency of the workforce at the company, Baudax Bio Inc. [BXRX] managed to generate an average of -$1,335,088 per employee. Receivables Turnover for the company is 19.33 with a Total Asset Turnover recorded at a value of 0.01.Baudax Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.20.
An analysis of insider ownership at Baudax Bio Inc. [BXRX]
There are presently around $2 million, or 11.40% of BXRX stock, in the hands of institutional investors. The top three institutional holders of BXRX stocks are: VANGUARD GROUP INC with ownership of 3,740,262, which is approximately 0.334% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 1,329,684 shares of the stock with an approximate value of $0.28 million in BXRX stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.14 million in BXRX stock with ownership of nearly 27.291% of the company’s market capitalization.
Positions in Baudax Bio Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 9 institutional holders increased their position in Baudax Bio Inc. [NASDAQ:BXRX] by around 635,137 shares. Additionally, 18 investors decreased positions by around 655,749 shares, while 13 investors held positions by with 6,032,034 shares. The mentioned changes placed institutional holdings at 7,322,920 shares, according to the latest SEC report filing. BXRX stock had 2 new institutional investments in for a total of 82,961 shares, while 9 institutional investors sold positions of 232,175 shares during the same period.